NewsBenzingaAclaris avvia uno studio di fase 2b su modzatinib nel lichen planus, inibitore duale ITK/JAK3 con designazione Fast Track e potenziale prima terapia orale meccanisticamente completa Aclaris avvia uno studio di fase 2b su modzatinib nel lichen planus, inibitore duale ITK/JAK3 con designazione Fast Track e potenziale prima terapia orale meccanisticamente completa Benzinga 2026.11.16 08:35 (GMT+0) Open on Benzinga Other news Musk: Expects SpaceX to sell no compute to OpenAI Wall Street prepares for Anthropic IPO frenzy, despite broader AI stock slump Iron Mountain Stock: Is Wall Street Bullish or Bearish? HTX DeepThink: Leverage Flush-Out May Not Mark a Bottom; Weak Spot Demand Could Keep BTC Under Pressure What Wall Street analysts are now saying after Nvidia’s beat-and-raise quarter More Than a Swap: PancakeSwap Rebrands as Pancake Ahead of Mobile App Launch
HTX DeepThink: Leverage Flush-Out May Not Mark a Bottom; Weak Spot Demand Could Keep BTC Under Pressure